<?xml version='1.0' encoding='utf-8'?>
<document id="31506301"><sentence text="Systematic Development and Verification of a Physiologically Based Pharmacokinetic Model of Rivaroxaban."><entity charOffset="92-103" id="DDI-PubMed.31506301.s1.e0" text="Rivaroxaban" /></sentence><sentence text="Rivaroxaban is indicated for stroke prevention in nonvalvular atrial fibrillation (AF)"><entity charOffset="0-11" id="DDI-PubMed.31506301.s2.e0" text="Rivaroxaban" /></sentence><sentence text=" Its elimination is mediated by both hepatic metabolism and renal excretion" /><sentence text=" Consequently, its clearance is susceptible to both intrinsic (pathophysiological) and extrinsic (concomitant drugs) variabilities that in turn implicate bleeding risks" /><sentence text=" Upon systematic model verification, physiologically based pharmacokinetic (PBPK) models are qualified for the quantitative rationalization of complex drug-drug-disease interactions (DDDIs)" /><sentence text=" Hence, this study aimed to develop and verify a PBPK model of rivaroxaban systematically"><entity charOffset="63-74" id="DDI-PubMed.31506301.s6.e0" text="rivaroxaban" /></sentence><sentence text=" Key parameters required to define rivaroxaban's disposition were either obtained from in vivo data or generated via in vitro metabolism and transport kinetic assays" /><sentence text=" Our developed PBPK model successfully predicted rivaroxaban's clinical pharmacokinetic parameters within predefined success metrics" /><sentence text=" Consideration of basolateral organic anion transporter 3 (OAT3)-mediated proximal tubular uptake in tandem with apical P-glycoprotein (P-gp)-mediated efflux facilitated mechanistic characterization of the renal elimination of rivaroxaban in both healthy and renal impaired patients"><entity charOffset="227-238" id="DDI-PubMed.31506301.s9.e0" text="rivaroxaban" /></sentence><sentence text=" Retrospective drug-drug interaction (DDI) simulations, incorporating in vitro metabolic inhibitory parameters, accurately recapitulated clinically observed attenuation of rivaroxaban's hepatic clearance due to enzyme-mediated DDIs with CYP3A4/2J2 inhibitors (verapamil and ketoconazole)"><entity charOffset="260-269" id="DDI-PubMed.31506301.s10.e0" text="verapamil" /><entity charOffset="274-286" id="DDI-PubMed.31506301.s10.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.31506301.s10.e0" e2="DDI-PubMed.31506301.s10.e0" /><pair ddi="false" e1="DDI-PubMed.31506301.s10.e0" e2="DDI-PubMed.31506301.s10.e1" /></sentence><sentence text=" Notably, transporter-mediated DDI simulations between rivaroxaban and the P-gp inhibitor ketoconazole yielded minimal increases in rivaroxaban's systemic exposure when P-gp-mediated efflux was solely inhibited, but were successfully characterized when concomitant basolateral uptake inhibition was incorporated in the simulation"><entity charOffset="55-66" id="DDI-PubMed.31506301.s11.e0" text="rivaroxaban" /><entity charOffset="90-102" id="DDI-PubMed.31506301.s11.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.31506301.s11.e0" e2="DDI-PubMed.31506301.s11.e0" /><pair ddi="false" e1="DDI-PubMed.31506301.s11.e0" e2="DDI-PubMed.31506301.s11.e1" /></sentence><sentence text=" In conclusion, our developed PBPK model of rivaroxaban is systematically verified for prospective interrogation and management of untested yet clinically relevant DDDIs pertinent to AF management using rivaroxaban"><entity charOffset="44-55" id="DDI-PubMed.31506301.s12.e0" text="rivaroxaban" /><entity charOffset="203-214" id="DDI-PubMed.31506301.s12.e1" text="rivaroxaban" /><pair ddi="false" e1="DDI-PubMed.31506301.s12.e0" e2="DDI-PubMed.31506301.s12.e0" /><pair ddi="false" e1="DDI-PubMed.31506301.s12.e0" e2="DDI-PubMed.31506301.s12.e1" /></sentence><sentence text=" SIGNIFICANCE STATEMENT: Rivaroxaban is susceptible to DDDIs comprising renal impairment and P-gp and CYP3A4/2J2 inhibition"><entity charOffset="25-36" id="DDI-PubMed.31506301.s13.e0" text="Rivaroxaban" /></sentence><sentence text=" Here, systematic construction and verification of a PBPK model of rivaroxaban, with the inclusion of a mechanistic kidney component, provided insight into the previously arcane role of OAT3-mediated basolateral uptake in influencing both clinically observed renal elimination of rivaroxaban and differential extents of transporter-mediated DDIs"><entity charOffset="67-78" id="DDI-PubMed.31506301.s14.e0" text="rivaroxaban" /><entity charOffset="280-291" id="DDI-PubMed.31506301.s14.e1" text="rivaroxaban" /><pair ddi="false" e1="DDI-PubMed.31506301.s14.e0" e2="DDI-PubMed.31506301.s14.e0" /><pair ddi="false" e1="DDI-PubMed.31506301.s14.e0" e2="DDI-PubMed.31506301.s14.e1" /></sentence><sentence text=" The verified model holds potential for investigating clinically relevant DDDIs involving rivaroxaban and designing dosing adjustments to optimize its pharmacotherapy in atrial fibrillation"><entity charOffset="90-101" id="DDI-PubMed.31506301.s15.e0" text="rivaroxaban" /></sentence><sentence text="" /></document>